Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced NSCLC October 31, 2023
MHLW approves Phesgo, the Fixed-Dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast and Colorectal Cancer October 3, 2023
Ph 3 Trial of TUKYSA + ado-trastuzumab emtansine Meets Primary Endpoint of PFS in Patients with Previously Treated HER2+ve Metastatic Breast Cancer August 23, 2023
ACE-Breast-02 Pivotal Ph 3 Study of ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results March 15, 2023
Enhertu approved in China for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens February 28, 2023
ENHERTU® Approved in Japan for Patients with Previously Treated HER2 Positive Metastatic Breast Cancer November 30, 2022
